전체메뉴 닫기

About

Vision
& Mission

History

Corporate
Identity

Subsidiaries

Directions

Business

Overview

i-Cord Cord Blood Bank

Bio
Insurance

CHAUM

IT

CDMO

Overview of Matica BioLabs

Consulting

Genomics

R&D: Pipelines

Investors: Business Performance; IR
Presentations

ESG

ESG
Management

Environmental

Social

Governance

Articles of Incorporation

Board of Directors

Vision
& Mission

History

Corporate
Identity

About

History

2025

Matica Biotechnology Signs Strategic Agreement with Texas A&M University for CGT Research and Development
Matica Bio Labs Selected as an Executing Organization for the “2025 CMC Strategic Consulting” Project by the Korea Drug Development Fund
Consolidated Revenue Surpasses KRW 1 Trillion in 2024
Matica Biotechnology Signs CDMO Contract with U.S.-based Child’s Cure
Matica Biotechnology Signs Strategic Agreement with Texas A&M University for CGT R&D
CHA Biotech’s Phase I Clinical Trial for Premature Ovarian Failure Cell Therapy Confirms Safety
CHA Biotech’s TIL Cell Therapy for Recurrent Ovarian Cancer, ‘CHATIL,’ Selected as National New Drug Development Project
CHA Biotech’s ‘CHA Stem Cell Institute’ Named ‘Best Corporate Research Institute,’ Awarded by Ministry of Science and ICT
CHA Bio Group Holds Topping-out Ceremony for ‘CGB (Cell Gene Biobank)'
CHA Biotech and Sartorius Korea Biotech Sign MOU for Global Stem Cell Line Establishment and Large-scale Manufacturing Process Development

2024

Matica Biotechnology initiates development of a pediatric brain tumor therapy in collaboration with U.S.-based Treovir
Matica Biotechnology develops a virus capsid separation and analysis method
Matica Biotechnology signs a letter of intent (LOI) with U.S.-based KaliVir Immunotherapeutics for CDMO services
Matica Biotechnology enters into CDMO agreements with U.S.-based CytoImmune Therapeutics and Mongoose Bio
Selection of CBT101, an immune cell therapy for solid tumors, for government support under the National New Drug Development Program
Achievement of ISO27001:2022 certification for international information security standards
Joint development with CHA Vaccine Institute on a cancer therapy combining NK cells and immune boosters
Technology transfer agreement with U.S.-based CanCure for MIC-targeted antibody technology
Matica Biotechnology appoints CEO Paul Kim, a leading biotech and investment expert
Patent secured for the production method and material for highly activated NK cells
Launch of research on the anticancer efficacy of NK cell therapy using cationic polymers
CDMO contract signed with Cell in Cells for organoid-based therapies
Expanded collaboration with Centenaire Biosciences for combination studies involving NK cells and antibodies

CHA Network

Company Name CHA Biotech Co., Ltd.
CEO Suk Yoon Choi

[Main Office] CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea

TEL: +82-31-881-7400
FAX: +82-31-881-7524
IR Hotline: +82-31-780-7418

[Head Office] P&FOLUS Building, 442 Dosan-daero, Gangnam-gu, Seoul, Korea
[Business Hours] 09:00 AM – 06:00 PM

COPYRIGHT ⓒ 2025 CHA Biotech, All rights reserved.

Affiliates

Global Healthcare

Related

Business